多发性骨髓瘤预后分层研究进展

The progress on prognostic stratification of multiple myeloma

多发性骨髓瘤(multiple myeloma,MM)是一种浆细胞恶性增殖性疾病,生物学异质性强,个体间临床疗效差异大,生存期从数月至数十年不等。构建准确的预后分层评估体系已成为MM临床研究的发展趋势。分子遗传学是影响MM预后的主要内在因素,建立以分子遗传学为基础的新预后分层模式,综合疾病的宿主因素、肿瘤负荷、肿瘤生物学因素等各项指标及治疗反应的预后分层从而进行个体化治疗对现代MM治疗非常必要。

Multiple myeloma （MM） is a malignant neoplasm of hyperplastic plasma cells with biological heterogeneity and different clinical outcome between individuals with survival duration ranging from a few months to more than years. To establish an accurate prognostic stratification model is needed to stratify myeloma patients. Molecular genetics is the main internal factors affecting the prognosis ofMM, a reliable tool based on the chromosomal abnormalities is very necessary for the stratification model, combining host- related prognostic factors and tumor variables.It would be appropriate and the development trend to target patients with alternative strategies for MM.